Turning Point Therapeutics Profit Margin

Turning Point Therapeutics (TPTX) currently reports a profit margin of -33130.6% as of June 2022. That compares with -283.3% in the prior-year period — down 11594.7% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Turning Point Therapeutics's profit margin history and peer comparisons.

Turning Point Therapeutics's profit margin decreased from -283.3% to -33130.6% — a 11594.7% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Turning Point Therapeutics's profit margin of -33130.6% is lower than the Healthcare sector average of 14.34%. That is roughly 231059.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Turning Point Therapeutics's current -33130.6% should be judged against Healthcare norms (sector average: 14.34%) and against TPTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -33130.6%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Turning Point Therapeutics, and consider following TPTX for alerts when major investors trade the stock.